WASHINGTON, Jan 18 (Reuters) - Omrix Biopharmaceuticals Inc., which develops biosurgical and passive immunotherapy products, on Wednesday said it is planning to issue up to $80.5 million in stock in an initial public offering.
WASHINGTON, Jan 18 (Reuters) - Omrix Biopharmaceuticals Inc., which develops biosurgical and passive immunotherapy products, on Wednesday said it is planning to issue up to $80.5 million in stock in an initial public offering.